Oncoheroes Biosciences has secured worldwide pediatric oncology rights for dovitinib from Novartis

Oncoheroes Biosciences shared a post on LinkedIn:

“As we kick off Childhood Cancer Awareness Month, we’re thrilled to share a major milestone in our fight against childhood cancer!

Oncoheroes Biosciences has secured exclusive worldwide pediatric oncology rights for dovitinib from Novartis. The opportunity to explore this potential option for pediatric cancer treatment marks a significant step forward in our mission to bring new hope to young patients.

With clinical trials on the horizon, we’re eager to investigate how dovitinib can make a difference for children facing bone sarcomas and other challenging pediatric cancers.

Let’s continue to push boundaries and bring innovative treatments to those who need them most.”

Read further.
Source: Oncoheroes Biosciences/LinkedIn

More posts featuring Oncoheroes Biosciences on oncodaily.com